Form 4 Filing for Matly David at Inhibrx Biosciences, Inc.

This filing details a Form 4 submission by Matly David, President of Inhibrx Biosciences, Inc. (INBX). On April 24, 2026, David Matly acquired 50,000 stock options with a right to buy Common Stock. The options have an exercise price of $129.06 and expire on April 24, 2036. Vesting begins on April 24, 2027, with 25% of the shares becoming exercisable, followed by monthly installments over 36 months, contingent on continuous service. Following this transaction, David Matly holds 50,000 shares/options. The transaction was reported on April 27, 2026.